Patents by Inventor Harald Kolmar
Harald Kolmar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11466050Abstract: The invention relates to a method for peptide synthesis, wherein said method comprises the steps of reacting a first amino acid or a first peptide with an ?-amine protected second amino acid in a solvent selected from the group consisting of water, alcohol, and a mixture of water and alcohol, and removing the ?-amine protecting group with a deprotecting solution. The invention further relates to protective agents, their use and an apparatus for carrying out a method for solid phase synthesis of peptides.Type: GrantFiled: September 29, 2015Date of Patent: October 11, 2022Assignee: SULFOTOOLS GMBHInventors: Sascha Knauer, Tobias Michael Louis Roese, Olga Avrutina, Harald Kolmar, Christina Uth
-
Patent number: 11130818Abstract: The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.Type: GrantFiled: August 4, 2016Date of Patent: September 28, 2021Assignee: MERCK PATENT GMBHInventors: Birgit Piater, Ulrich Betz, Harald Kolmar, Vanessa Siegmund
-
Patent number: 11001640Abstract: The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.Type: GrantFiled: October 21, 2015Date of Patent: May 11, 2021Assignee: Merck Patent GmbHInventors: Stefan Becker, Bjoern Hock, Stefan Zielonka, Harald Kolmar, Martin Empting
-
Publication number: 20190194344Abstract: The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.Type: ApplicationFiled: August 4, 2016Publication date: June 27, 2019Applicant: Merck Patent GmbHInventors: Birgit Piater, Ulrich Betz, Harald Kolmar, Vanessa Siegmund
-
Publication number: 20180171020Abstract: The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.Type: ApplicationFiled: October 21, 2015Publication date: June 21, 2018Applicant: Merck Patent GmbHInventors: Stefan Becker, Bjoern Hock, Stefan Zielonka, Harald Kolmar, Martin Empting
-
Patent number: 9733240Abstract: A generally applicable method for the selective covalent attachment of a reporter molecule to a replicating entity that allows one to obtain specific binders from a single round of library screening is disclosed. For example, selective biotinylation of phage particles and yeast cells displaying a binder to any given target can be achieved via application of a coupled enzyme reaction that includes a peroxidase, an oxidase and a catalase.Type: GrantFiled: December 14, 2012Date of Patent: August 15, 2017Assignee: Merck Patents GmbHInventors: Stefan Becker, Tim Heiseler, Alexander Maass, Harald Kolmar
-
Publication number: 20170218010Abstract: The invention relates to a method for peptide synthesis, wherein said method comprises the steps of reacting a first amino acid or a first peptide with an ?-amine protected second amino acid in a solvent selected from the group consisting of water, alcohol, and a mixture of water and alcohol, and removing the ?-amine protecting group with a deprotecting solution. The invention further relates to protective agents, their use and an apparatus for carrying out a method for solid phase synthesis of peptides.Type: ApplicationFiled: September 29, 2015Publication date: August 3, 2017Inventors: Sascha KNAUER, Tobias Michael Louis ROESE, Olga AVRUTINA, Harald KOLMAR, Christina UTH
-
Publication number: 20160194380Abstract: The present invention pertains to highly potent Matriptase inhibitors derived from the miniprotein McotI-II.Type: ApplicationFiled: April 8, 2014Publication date: July 7, 2016Applicant: Merck Patent GmbHInventors: Michael TOMASZOWSKY, Niklas WEBER, Bernhard GLOTZBACH, Harald KOLMAR, Bjoern HOCK
-
Publication number: 20160016998Abstract: The present invention relates to novel matriptase inhibitors.Type: ApplicationFiled: January 9, 2014Publication date: January 21, 2016Applicant: Merck Patent GmbHInventor: Harald KOLMAR
-
Publication number: 20140357514Abstract: A generally applicable method for the selective covalent attachment of a reporter molecule to a replicating entity that allows one to obtain specific binders from a single round of library screening is disclosed. For example, selective biotinylation of phage particles and yeast cells displaying a binder to any given target can be achieved via application of a coupled enzyme reaction that includes a peroxidase, an oxidase and a catalase.Type: ApplicationFiled: December 14, 2012Publication date: December 4, 2014Inventors: Stefan Becker, Tim Heiseler, Alexander Maass, Harald Kolmar
-
Patent number: 8278262Abstract: Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein.Type: GrantFiled: September 19, 2005Date of Patent: October 2, 2012Assignee: BioNTech AGInventors: Harald Kolmar, Christian Sommerhoff, Alexander Wentzel
-
Patent number: 8258258Abstract: Disclosed is a polypeptide comprising at least two microproteins, which preferably comprise an amino acid sequence having a specific binding activity to a target protein. Furthermore, disclosed are polynucleotides encoding such a polypeptide as well as pharmaceutical compositions and kits comprising said polypeptide or polynucleotide. Also disclosed herein are methods of treatments and second medical uses applying the disclosed polypeptide or polynucleotide. Additionally, the disclosure of the present application relates to a method for forming a covalent bond in a microprotein which can be used for producing the disclosed polypeptides.Type: GrantFiled: March 9, 2006Date of Patent: September 4, 2012Assignee: BioNTech AGInventors: Harald Kolmar, Ernst Boehnlein, Alexander Wentzel, Hans-Ulrich Schmoldt
-
Publication number: 20100267610Abstract: A polypeptide, with an amino acid sequence different from that of knottin protein, having a scaffold moiety with a helix moiety inserted in the scaffold moiety is described. The scaffold moiety comprises a knottin protein, or a fragment of knottin protein.Type: ApplicationFiled: February 18, 2008Publication date: October 21, 2010Applicant: BIONTECH AGInventors: Michael Blind, Harald Kolmar
-
Publication number: 20090156476Abstract: Disclosed is a polypeptide comprising at least two microproteins, which preferably comprise an amino acid sequence having a specific binding activity to a target protein. Furthermore, disclosed are polynucleotides encoding such a polypeptide as well as pharmaceutical compositions and kits comprising said polypeptide or polynucleotide. Also disclosed herein are methods of treatments and second medical uses applying the disclosed polypeptide or polynucleotide. Additionally, the disclosure of the present application relates to a method for forming a covalent bond in a microprotein which can be used for producing the disclosed polypeptides.Type: ApplicationFiled: March 9, 2006Publication date: June 18, 2009Applicant: NascaCell Technologies AGInventors: Harald Kolmar, Ernst Boehnlein, Alexander Wentzel, Hans-Ulrich Schmoldt
-
Publication number: 20090130692Abstract: Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein.Type: ApplicationFiled: September 19, 2005Publication date: May 21, 2009Applicant: Nasca Cell Technologies AGInventors: Harald Kolmar, Christian Sommerhoff, Alexander Wentzel
-
Patent number: 7186524Abstract: The inventive method allows peptides or polypeptides to be exposed on the surface of gram-negative host bacteria using specific intimin-based anchor modules. Intimins with shortened carboxy terminals have been found to be particularly suitable anchor modules for passenger domains in the exterior E. coli cell membrane. According to the method, host bacteria are transformed using vectors, on which are located a fused nucleic acid sequence consisting of a sequence segment which codes for an intimin with a shortened carboxy terminal and a nucleic acid sequence segment which codes for the passenger peptide that is to be exposed. The invention permits a particularly large number of passenger domains to be exposed on the cell surface of the bacteria, without adversely affecting the viability of the bacteria.Type: GrantFiled: October 25, 2001Date of Patent: March 6, 2007Assignee: NascaCell Technologies AGInventors: Harald Kolmar, Andreas Christmann, Alexander Wentzel
-
Publication number: 20040106118Abstract: The inventive method allows peptides or polypeptides to be exposed on the surface of gram-negative host bacteria using specific intimin-based anchor modules. Intimins with shortened carboxy terminals have been found to be particularly suitable anchor modules for passenger domains in the exterior E.coli cell membrane. According to said method, host bacteria are transformed using vectors, on which are located a fused nucleic acid sequence consisting of a sequence segment which codes for an intimin with a shortened carboxy terminal and a nucleic acid sequence segment which codes for the passenger peptide that is to be exposed. The invention permits a particularly large number of passenger domains to be exposed on the cell surface of the bacteria, without adversely affecting the viability of the bacteria.Type: ApplicationFiled: October 15, 2003Publication date: June 3, 2004Inventors: Harald Kolmar, Andreas Christmann, Alexander Wentzel
-
Patent number: 5882924Abstract: The invention relates to a process for the genetic selection in microorganisms of proteins which are capable of ligand binding, in which process a protein which is capable of ligand binding is presented extracytoplasmically and the signal of the ligand binding is passed on by signal transduction to the biosynthetic machinery of the micoorganism for the purpose of expressing a detectable and/or selectable function. In addition to this, the patent discloses microorganisms which are suitable for use in this process, as well as replicons and processes for their preparation.Type: GrantFiled: October 22, 1997Date of Patent: March 16, 1999Assignee: Behringwerke AktiengesellschaftInventors: Hans-Joachim Fritz, Frank Hennecke, Harald Kolmar